Table 2.
Clinical trials on piperine*
| Condition & (number of patients) | Phases I, II, III or IV & (Status) | Dose, duration | Principal Investigator affiliation | Duration (months) | References |
|---|---|---|---|---|---|
|
KOA (60) |
I (Completed) |
7.5 mg/day, 4 wks | Motahar Heidari-Beni, IUMS |
Jan 2018–May 2018 (5) |
Heidari-Beni et al. [154] |
|
TCS 12) |
I (Completed) |
20 mg/day,10 days | S. K. Bedada, UCPSKU |
2016–2016 – |
Bedada et al. [155, 156] |
|
MS (12) |
I (Completed) |
20 mg/day, 2 days | HMO & A. Hoffman and A. Domb, DRBCPHU |
Aug 2013–Jan 2015 (17) |
Cherniakov et al. [157] |
|
AIDS (08) |
I (Completed) |
20 mg/day,7 days | Ravisekhar Kasibhatta, BCRPL, Hyderabad |
2007–2008 – |
Kasibhatta and Naidu [158] |
|
NAFLD (79) |
III (Completed) |
5 mg/day, 8 weeks | Dr. Abasalt Borji, NUMS |
Jan 2017–Nov 2017 (10) |
Mirhafez et al. [159] |
|
T2DM (100) |
III (Ongoing) |
5 mg/day, 12weeks |
Jun 2015–Present (12) |
* | |
|
NAFLD (70) |
II (Ongoing) |
5 mg/day, 12weeks |
Jan 2018–Present – |
||
|
HIVS (60) |
I (Completed) |
– | Philip C Smith, School of Pharmacy, UNC Chapel Hill |
Sep 2003–Mar 2006 (30) |
|
|
MN, Pain, BS, Urinary Urgency (09) |
I (Active, not recruiting) |
– | Aminah Jatoi, Mayo Clinic, Rochester, Minnesota, United States |
Mar 2016–Mar 2021 (60) |
|
|
CKD (30) |
NA (Recruiting) |
500 mg of curcumin and piperine, 3 capsules/day, 12 weeks | Denise Mafra, Federal University Fluminense, Rio de Janeiro, Brazil |
Oct 2020–Oct 2021 (12) |
|
|
Hair Thinning (70) |
NA Recruiting) |
95% piperine extract in formulation, 4 capsules/ day, 180 days | Glynis Ablon, ABSIRC, Manhattan Beach, California, United States |
Jun 2019–Jan 2021 (18) |
|
|
Epilepsy (10) |
I (Completed) |
20 mg/day, 2 days | Smita Pattanaik, NOD-PGIMER, Chandigarh, India |
2017–2017 – |
Pattanaik et al. [160] |
|
OD (40) |
I&II (Completed) |
Group1 = 150 μM Group 2 = 1 mM |
Laia Rofes, GPLRU, Hospital de Mataro´, Spain |
Jun 2011–Feb 2012 (9) |
Rofes et al. [161] |
|
MS (12) |
I (Completed) |
20 mg/day, 10 days | S K Bedada, UCPSKU |
2016–2016 – |
Bedada and Boga [162] |
|
OA (53) |
III (Completed) |
15 mg/day, 6 weeks | Dr. Yunes Panahi, CIRC-BUC, CRDU-BH, BUMS, Iran |
Jan 2011–Jan 2012 (12) |
Panahi et al. [163–165] |
|
Vitiligo (63) |
II&III (Completed) |
1% Topical solution, 12weeks | Anoosh Shafiee, SRC-SBUM, Iran |
Jun 2016–Sep 2016 (3) |
Shafiee et al. [15] |
* Referenced from:—US National Library of Medicine: https://www.clinicaltrials.gov/ct2/results?cond=&term=piperine&cntry=&state=&city=&dist = ; University hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR): https://www.umin.ac.jp/ctr/index.htm & Iranian Registry of Clinical Trials: https://www.irct.ir/